Progress in the treatment of a neglected infectious disease: Visceral leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 279-292

  Murray, Henry W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Amphotericin B; Cytokines; Immunochemotherapy; Kala azar; Lipid formulated amphotericin B; Miltefosine; Paromyomycin; Pentavalent antimony; Sitamaquine; Visceral leishmaniasis

Indexed keywords

ALLOPRIM; ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANISOMYCIN; ANTIMONY DERIVATIVE; ATOVAQUONE PLUS PROGUANIL; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUCONAZOLE; GAMMA INTERFERON; GENERIC DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INDOMETACIN; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4 ANTIBODY; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUCARESOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; BANGLADESH; BRAZIL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; IMMUNOSTIMULATION; IMMUNOTHERAPY; INDIA; LIVER TOXICITY; MALE INFERTILITY; NAUSEA; NEPAL; NEPHROTOXICITY; OTOTOXICITY; POVERTY; PROTOZOAL INFECTION; RETINA DISEASE; REVIEW; RURAL AREA; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SUDAN; TERATOGENICITY; UREMIA; VISCERAL LEISHMANIASIS; VOMITING;

EID: 2942620631     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.279     Document Type: Review

References (77)

1. Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis and treatment and a proposed research and development agenda. Lancet Infect. Dis. 2, 494-501 (2002).
2. Herwaldt BL. Leishmaniasis. Lancet. 54, 1191-1199 (1999).
3. Murray HW. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob. Agents Chemother. 45, 2185-2197 (2001)
4. Murray HW. Kala-azar - progress against a neglected disease. N. Engl. J. Med. 347, 1793-1794 (2002).
5. Seaman J, Mercer AJ, Sandorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol. 25, 862-871 (1996).
6. Pintado V, Martin-Rabadan P, Rivera ML, Morneo S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80, 54-73 (2001).
7. Ritmeijer K, Veeken H, Melaku Y et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg. 95, 668-672 (2001).
8. Berman J. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16, 397-401 (2003).
9. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104-1106 (2000).
10. Das VN, Ranjan A, Sinha AN et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India 49, 609-613 (2001).
11. Dietze R, Fagundes S, Brito E et al. Treatment of kata-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Trop. Med. Hyg. 89, 309-311 (1995).
12. Davidson RN, di Martino L, Gradoni L et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22, 938-943 (1996).
13. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann. Intern. Med. 127, 133-137 (1997).
14. Seaman J, Boer C, Wilkinson R et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21, 188-193 (1995).
15. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull. World Health Organ. 73, 191-197 (1999).
16. Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg. Infect. Dis. 9, 1617-1620 (2003).
17. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84, 221-225 (1990).
18. Seaman J, Pryce D, Sondorp H, Wilkinson R, Bryceson ADM. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168, 715-720 (1994).
19. Jha TK, Olliaro P, Thakur CP et al. Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br. Med. J. 61, 1200-1205 (1998).
20. Thakur CP, Kanyok TP, Pandey AK et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromyomycin (aminosidine) plus sodium stibogluconte versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94, 420-431 (2000).
21. Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352, 1821-1823 (1998).
22. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347, 1739-1746 (2002).
23. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4, 158-177 (2000).
24. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15, 593-598 (2002).
25. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate (Pentostam, Glaxo Wellcome, London, UK) and generic sodium stibogluconate for visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health 5, 312-317 (2002).
26. Moore E, O'Flaherty, Heuvelmans H et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. 79, 388-393 (2001).
27. Syriopoulou V, Daikos GL, Theodoridou M et al. Two doses of a lipid formulation of amphoericin B for the treatment of Mediterranean visceral leishmaniasis. Clin. Infect. Dis. 36, 560-566 (2003).
28. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Trop. Med. Hyg. 93, 319-323 (1999).
29. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis - a multicenter study. Am. J. Trop. Med. Hyg. 66, 143-146 (2002).
30. Sundar S, Mehra H, Sures AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional vs. lipid-formulations. Clin. Infect. Dis. 38, 377-383 (2004).
31. Gaeta GB, Maisto A, Di Caprio D et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand. J. Infect. Dis. 32, 675-677 (2000).
32. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimircob. Agents Chemother. 46, 828-833 (2002).
33. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. Br. Med. J. 323, 419-242 (2001).
34. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37, 800-804 (2003).
35. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis. Ann. Trop. Med. Parasitol. 92, 755-764 (1998).
36. Berman JD, Badaro R, Thakur CP et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76, 25-32 (1998).
37. Sundar S, Gupta LB, Rastogi V, Agrawal G, Murray HW. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 94, 200-204 (2000).
38. Bodhe PV, Kotwani RN, Kirodian BG et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 93, 314-318 (1999).
39. Pagliano P, Rossi M, Rescigno, C et al. Mediterranean visceral lishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). J. Antimicrob. Chemother. 52, 264-268 (2003).
40. Ostrosky-Zeichner L, Mart KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37, 415-425 (2003).
41. Yeates C. Sitamaquine. Curr. Opin. Invest. Drugs 3, 1446-1452 (2002).
42. Sherwood J, Gachihi G, Muigai R et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 19, 1034-1039 (1994).
43. Wasunna M, Rashid JR, Nyakundi PM et al. Sitamaquine (SB-25220, B WR6026) in the oral treatment of visceral leishmaniasis. Second World Congress on Leishmaniaisis.(2001) (Abstract 125).
44. Dietze R, Carvalho SF, Muigai RK et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65, 685-689 (2001).
45. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36, 2633-2636 (1987).
46. Sundar S, Sundar S, Gupta LB et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 93, 589-597 (1999).
47. Jha TK, Sundar S, Thakur CP et al. Efficacy and toxicity of miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341, 1795-1800 (1999).
48. Sundar S, Makharia A, More DK et al. Short-course oral miltefosine treatment for visceral leishmaniasis. Clin. Infect. Dis. 31, 1110-1103 (2000).
49. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr. Infect. Dis. 22, 434-438 (2003).
50. Bhattacharya SK, Jha TK, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. 38, 217-221 (2004).
51. Alvar J, Canavate C, Gutierrez-Solar B et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol Rev. 10, 298-319 (1997).
52. de la Rosa R, Pineda JA, Delgado J et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 32, 633-635 (2001).
53. Laguna F, Lopez-Velez R, Pulido F et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 13, 1063-1070 (1999).
54. Laguna F, Videla S, Jimenez-Mejias ME et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother. 52, 464-469 (2003).
55. Murray HW. Suppression of post-treatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44, 3235-3236 (2000).
56. Fernandez-Cotarelo MJ, Abellan-Martinez JA, Guerra-Vales JM et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 37, 973-977 (2003).
57. Berenguer J, Gomez-Campdera F, Padilla B et al. Visceral leishmaniasis (kala-azar) in transplant recipients. Transplantation 65, 1401-1404 (1998).
58. Hernandez-Perez J, Yebra-Bango M, Jimenez-Martinez E et al. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin. Infect. Dis. 29, 918-921 (1999).
59. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8, 319-342 (2002).
60. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19, 502-508 (2003).
61. Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol. 20, 73-76 (2004).
62. Wilson ME, Young BM, Davidson BL, Menta KA, McGowan SE. The importance of TGF-β in murine visceral leishmaniasis. J. Immunol. 161, 6148-6155 (1998).
63. Murphy ML, Cotterell S, Gorak M, Engwerda CR, Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161, 4153-4160 (1998).
64. Melby PC, Yang Y-Z, Cheng J, Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66, 18-27 (1998).
65. Murray HW. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82, 249-267 (2001),
66. Murray, HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immuno- or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71, 6453-6462 (2003).
67. Awasthi A, Mathur R, Khan A et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MARK activator establishing a host-protective memory T-cell response. J. Exp. Med. 197,1037-1043 (2003).
68. Murray, HW, C.M. Lu CM, S. Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70, 6284-6293 (2002).
69. Murray, HW, Brooks EB, DeVecchio JL, Heinzel FP. Immunoenhancement combined with amphotericin B as treatment in experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 47, 2513-2517 (2003).
70. Badaro R, Nascimento C, Carvalho J et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170, 413-418 (1994).
71. Murray HW, Moreira AL, Lu CM et al. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 188, 458-464 (2003).
72. Karp C, Wynn T, Satti M et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91, 1644-1648 (1993).
73. Ghalib H, Piuvezam M, Skeily Y et al. Interleukin-10 production correlates with pathology in human Leishmania donovani infection. J. Clin. Invest. 92, 324-329 (1993).
74. Sundar S, Reed SG, Sharma S, Mehrota A, Murray HW. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56, 522-526 (1997).
75. Gasim A, El-Hassan A, Khalil AE et al. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111, 64-69 (1998).
76. Barcellar O, D'Oliveira A, Jeronimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12, 1228-1231 (2000).
77. Murray HW. interleukin-10 receptor blockade-pentavalent antimony treatment in experimental visceral leishmaniasis (submitted).